SCHEMBL21955320

SCHEMBL21955320

Cc1c(-c2ccc(CC(N)C(=O)O)c3c2COC3)c(=O)n(C)c(=O)n1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 9/20 0.39
ITGA4 P13612 9/20 0.39
ITGB7 P26010 9/20 0.39
ALDH1A1 P00352 2/20 0.31
MAPT P10636 2/20 0.31
RECQL P46063 2/20 0.31
NOS3 P29474 1/20 0.31
NOS1 P29475 1/20 0.31
NOS2 P35228 1/20 0.31
USP2 O75604 2/20 0.30
KDM4E B2RXH2 2/20 0.30
RGS12 O14924 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2C9 P11712 1/20 0.30
PKM P14618 1/20 0.30
ALOX15 P16050 1/20 0.30
NFKB1 P19838 1/20 0.30
CASP1 P29466 1/20 0.30
BRCA1 P38398 1/20 0.30
THPO P40225 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21955318 1.00 ITGB1 (0.39) ITGB1ITGA4ITGB7ALDH1A1MAPT
SCHEMBL22016797 0.89 ITGB1 (0.36) ITGB1ITGA4ITGB7L3MBTL1
SCHEMBL21954933 0.81 ITGB1 (0.41) ITGB1ITGA4ITGB7ALDH1A1MAPT
SCHEMBL21954932 0.81 ITGB1 (0.41) ITGB1ITGA4ITGB7ALDH1A1MAPT
SCHEMBL21955188 0.78 ITGA4 (0.63) ITGB1ITGA4ITGB7
SCHEMBL21955186 0.78 ITGA4 (0.63) ITGB1ITGA4ITGB7
SCHEMBL21955013 0.72 CYP2C9 (0.38) ALDH1A1MAPTRECQLUSP2KDM4E
SCHEMBL21955012 0.72 CYP2C9 (0.38) ALDH1A1MAPTRECQLUSP2KDM4E
SCHEMBL18009483 0.72 ITGB1 (0.58) ITGB1ITGA4ITGB7PKM
SCHEMBL18009482 0.72 ITGB1 (0.58) ITGB1ITGA4ITGB7PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11224600-B2 Compounds for inhibition of alpha 4 beta 7 integrin GILEAD SCIENCES, INC. (US) 2022-01-18 US disclosed
EP-3873897-A1 COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN GILEAD SCIENCES, INC. (US) 2021-09-08 EP disclosed
CN-112996786-A Compounds for inhibiting alpha 4 beta 7 integrins 吉利德科学公司 2021-06-18 CN disclosed
US-20200155563-A1 COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN GILEAD SCIENCES, INC. 2020-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200155563-A1 COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN ITGB7, ITGB4, ITGA4 ITGB1 4/4885ITGA4 3/4885ITGB7 1/4885
US-11224600-B2 Compounds for inhibition of alpha 4 beta 7 integrin ITGB7, ITGB4, ITGA4 ITGB1 4/4885ITGA4 3/4885ITGB7 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.